Sar-Arg-Val-Tyr-Ile-His-Pro-Ala-OH

a beta-arrestin biased ligand of the angiotensin II type 1 receptor that competitively antagonizes angiotensin II-stimulated G protein signaling, but stimulates β-arrestin recruitment and activates several kinase pathways

Also Known As:

Networked: 14 relevant articles (2 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Soergel, David G: 5 articles (02/2018 - 11/2011)
2.	Violin, Jonathan D: 4 articles (03/2015 - 11/2011)
3.	Lark, Michael W: 3 articles (09/2013 - 11/2011)
4.	Kawagishi, Hiroyuki: 2 articles (01/2021 - 11/2020)
5.	Yamada, Mitsuhiko: 2 articles (01/2021 - 11/2020)
6.	Butler, Javed: 2 articles (02/2018 - 03/2015)
7.	Collins, Sean P: 2 articles (02/2018 - 03/2015)
8.	Cotter, Gad: 2 articles (02/2018 - 03/2015)
9.	Davison, Beth A: 2 articles (02/2018 - 03/2015)
10.	Ezekowitz, Justin A: 2 articles (02/2018 - 03/2015)

Related Diseases

1.	Heart Failure 01/01/2015 - "Because of this unique pharmacological profile, TRV027 is now being evaluated in a phase II clinical trial as a novel therapeutic for acute heart failure (AHF)." 09/01/2012 - "These results provide support for TRV120027 as a promising novel therapeutic for the treatment of heart failure." 09/01/2013 - "Further clinical studies with TRV027 in patients with heart failure are underway. " 09/01/2013 - "In preclinical studies, TRV027 reversibly reduced blood pressure while preserving renal function in a dog tachypaced heart failure model and stimulating cardiomyocyte contractility in vitro. " 11/01/2020 - "Thus, TRV027 could be utilized as a valuable drug specific for pediatric heart failure."
2.	COVID-19 01/01/2023 - "The effect of TRV027 on coagulation in COVID-19: A pilot randomized, placebo-controlled trial." 01/01/2023 - "We undertook a double-blind randomized, placebo-controlled experimental medicine study to assess the effect of TRV027, a synthetic angiotensin-1-7 analogue on D-dimer in 30 patients admitted to hospital with COVID-19. " 11/01/2023 - "To evaluate the efficacy and safety of RAS modulation using 2 investigational RAS agents, TXA-127 (synthetic angiotensin [1-7]) and TRV-027 (an angiotensin II type 1 receptor-biased ligand), that are hypothesized to potentiate the action of angiotensin (1-7) and mitigate the action of the angiotensin II. Two randomized clinical trials including adults hospitalized with acute COVID-19 and new-onset hypoxemia were conducted at 35 sites in the US between July 22, 2021, and April 20, 2022; last follow-up visit: July 26, 2022. "
3.	Hypoxia (Hypoxemia) 11/01/2023 - "To evaluate the efficacy and safety of RAS modulation using 2 investigational RAS agents, TXA-127 (synthetic angiotensin [1-7]) and TRV-027 (an angiotensin II type 1 receptor-biased ligand), that are hypothesized to potentiate the action of angiotensin (1-7) and mitigate the action of the angiotensin II. Two randomized clinical trials including adults hospitalized with acute COVID-19 and new-onset hypoxemia were conducted at 35 sites in the US between July 22, 2021, and April 20, 2022; last follow-up visit: July 26, 2022. "
4.	Hypertension (High Blood Pressure) 01/01/2018 - "Furthermore, TRV027 induced lesser interactions between AT1R and ACE2 compared with Ang-II. Together, these data suggest that due to its biased activity for the β-arrestin pathway, TRV027 has beneficial effects within the CNS on hypertension, autonomic and vascular function, possibly through preserving ACE2 compensatory activity in neurones." 01/01/2021 - "We conclude that administration of TRV027 a selective β-arrestin biased agonist directly into the brain increases aversion to saline and lowers blood pressure in a model of salt-sensitive hypertension. "
5.	Fibrosis (Cirrhosis) 01/01/2023 - "Co-infusion with both TRV027 and Olmesartan prevented endoplasmic reticulum stress, fibrosis, and vasomotor hyper responsiveness. " 07/15/2023 - "Our results demonstrated that antagonism of angiotensin II type 1 receptor (AT1 receptor) and blockade of Gαq protein suppressed angiotensin II (Ang II)-induced fibroblast proliferation, overexpression of collagen I and α-smooth muscle actin (α-SMA), and stress fibre formation, indicating the AT1 receptor/Gαq axis is necessary for fibrogenic effects of Ang II. Stimulation of AT1 receptors by their Gαq-biased ligand (TRV120055), but not β-arrestin-biased ligand (TRV120027), substantially exerted fibrogenic effects at a level similar to that of Ang II, suggesting that AT1 receptor induced cardiac fibrosis in a Gαq-dependent and β-arrestin-independent manner. "

Related Drugs and Biologics

1.	Ligands
2.	Type 1 Angiotensin Receptor
3.	Angiotensin II
4.	Sodium
5.	Angiotensin Receptors (Angiotensin II Receptor)
6.	angiotensin I (1-7)
7.	fibrin fragment D (D-dimer)
8.	Arrestin
9.	Reactive Oxygen Species (Oxygen Radicals)
10.	Salts